Nanobodies®: Proficient tools in diagnostics

Expert Review of Molecular Diagnostics

Volumn 10, Issue 6, 2010, Pages 777-785

  Huang, Lieven ^a   Muyldermans, Serge ^b,c   Saerens, Dirk ^b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

antibody engineering; biosensor; camelid; diagnostic tool; immunodiagnostics; llama; molecular imaging; monoclonal antibody; Nanobody

Indexed keywords

ANTIBODY ENGINEERING; ANTIGEN ANTIBODY COMPLEX; ARTIODACTYLA; BIOSENSOR; CANCER RECURRENCE; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVOLUTION; HEAVY CHAIN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOSENSOR; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; REVIEW; TECHNOLOGY;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; CAMELIDS, NEW WORLD; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR PROBES;

EID: 77956717843     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.62     Document Type: Review

References (57)

1. Reichert JM. Antibodies to watch in 2010. MAbs 2(1), 84-100 (2010).
2. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat. Biotechnol. 23(9), 1105-1116 (2005).
3. Saerens D, Ghassabeh GH, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr. Opin. Pharmacol. 8(5), 600-608 (2008).
4. Barthelemy PA, Raab H, Appleton BA et al. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J. Biol. Chem. 283(6), 3639-3654 (2008).
5. Wesolowski J, Alzogaray V, Reyelt J et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol. 198(3), 157-174 (2009).
6. Dimitrov DS. Engineered CH2 domains (nanoantibodies). MAbs 1(1), 26-28 (2009).
7. Muyldermans S. Single domain camel antibodies: current status. J. Biotechnol. 74(4), 277-302 (2001).
8. Conrath K, Vincke C, Stijlemans B et al. Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J. Mol. Biol. 350(1), 112-125 (2005).
9. Desmyter A, Transue TR, Ghahroudi MA et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol. 3(9), 803-811 (1996).
10. De Genst E, Silence K, Decanniere K et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl Acad. Sci. USA 103(12), 4586-4591 (2006).
11. Vincke C, Loris R, Saerens D et al. General strategy to humanize a Camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 284(5), 3273-3284 (2009).
12. Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2(2), RESEARCH0004 (2001).
13. Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr. Opin. Investig. Drugs 10(11), 1212-1224 (2009).
14. Huang L, Reekmans G, Saerens D et al. Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays. Biosens. Bioelectron. 21(3), 483-490 (2005).
15. Rothbauer U, Zolghadr K, Muyldermans S et al. A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol. Cell Proteomics 7(2), 282-289 (2008).
16. Saerens D, Stijlemans B, Baral TN et al. Parallel selection of multiple anti-infectome Nanobodies without access to purified antigens. J. Immunol. Methods 329(1-2), 138-150 (2008).
17. Verheesen P, Roussis A, de Haard HJ et al. Reliable and controllable antibody fragment selections from camelid non-immune libraries for target validation. Biochim. Biophys. Acta. 1764(8), 1307-1319 (2006).
18. Stijlemans B, Conrath K, Cortez-Retamozo V et al. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J. Biol. Chem. 279(2), 1256-1261 (2004).
19. Deckers N, Saerens D, Kanobana K et al. Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosis. Int. J. Parasitol. 39(5), 625-633 (2009).
20. Antoine-Moussiaux N, Saerens D, Desmecht D. Flow cytometric enumeration of parasitaemia and hematologic changes in trypanosoma-infected mice. Acta. Trop. 107(2), 139-144 (2008).
21. Franco EJ, Sonneson GJ, Delegge TJ et al. Production and characterization of a genetically engineered anti-caffeine camelid antibody and its use in immunoaffinity chromatography. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 878(2), 177-186 (2010).
22. Ladenson RC, Crimmins DL, Landt Y, Ladenson JH. Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment. Anal. Chem. 78(13), 4501-4508 (2006).
23. Goldman ER, Anderson GP, Conway J et al. Thermostable llama single domain antibodies for detection of botulinum A neurotoxin complex. Anal. Chem. 80(22), 8583-8591 (2008).
24. Anderson GP, Goldman ER. TNT detection using llama antibodies and a two-step competitive fluid array immunoassay. J. Immunol. Methods 339(1), 47-54 (2008).
25. Anderson GP, Moreira SC, Charles PT et al. TNT detection using multiplexed liquid array displacement immunoassays. Anal. Chem. 78(7), 2279-2285 (2006).
26. Vo-Dinh T, Kasili P, Wabuyele M. Nanoprobes and nanobiosensors for monitoring and imaging individual living cells. Nanomedicine 2(1), 22-30 (2006).
27. Ryan S, Kell AJ, van Faassen H et al. Single-domain antibody- nanoparticles: promising architectures for increased Staphylococcus aureus detection specificity and sensitivity. Bioconjug. Chem. 20(10), 1966-1974 (2009).
28. Conroy PJ, Hearty S, Leonard P, OKennedy RJ. Antibody production, design and use for biosensor-based applications. Semin. Cell Dev. Biol. 20(1), 10-26 (2009).
29. Saerens D, Huang L, Bonroy K, Muyldermans S. Antibody fragments as probe in biosensor development. Sensors 8(8), 4669-4686 (2008).
30. Pleschberger M, Saerens D, Weigert S et al. An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology. Bioconjug. Chem. 15(3), 664-671 (2004).
31. Saerens D, Frederix F, Reekmans G et al. Engineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensing. Anal. Chem. 77(23), 7547-7555 (2005).
32. Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J. Nucl. Med. 50(1), 2-5 (2009).
33. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23(9), 1137-1146 (2005).
34. van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 12(12), 1379-1389 (2007).
35. Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Expert Opin. Drug Deliv. 3(1), 53-70 (2006).
36. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414(3), 521-526 (1997).
37. Huang L, Gainkam LO, Caveliers V et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol. Imaging Biol. 10(3), 167-175 (2008).
38. De Groeve K, Deschacht N, De Koninck C et al. Nanobodies as tools for in vivo imaging of specific immune cell types. J. Nucl. Med. 51(5), 782-789 (2010).
39. Penault-Llorca F, Cayre A, Arnould L et al. Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment? Oncol. Rep. 16(6), 1173-1179 (2006).
40. Roovers RC, Laeremans T, Huang L et al. Efficient inhibition of EGFR signaling and of tumor growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol. Immunother. 56(3), 303-317 (2007).
41. Vaneycken I, Govaert J, Vincke C et al. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/Micro-CT. J. Nucl. Med. 51(7), 1099-106 (2010).
42. Tijink BM, Laeremans T, Budde M et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol. Cancer Ther. 7(8), 2288-2297 (2008).
43. Gainkam LO, Huang L, Caveliers V et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J. Nucl. Med. 49(5), 788-795 (2008).
44. Olichon A, Surrey T. Selection of genetically encoded fluorescent single domain antibodies engineered for efficient expression in Escherichia coli. J. Biol. Chem. 282(50), 36314-36320 (2007).
45. Rothbauer U, Zolghadr K, Tillib S et al. Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat. Methods 3(11), 887-889 (2006).
46. Kirchhofer A, Helma J, Schmidthals K et al. Modulation of protein properties in living cells using nanobodies. Nat. Struct. Mol. Biol. 17(1), 133-138 (2010).
47. Schornack S, Fuchs R, Huitema E et al. Protein mislocalization in plant cells using a GFP-binding chromobody. Plant J. 60(4), 744-754 (2009).
48. Cruz HJ, Rosa CC, Oliva AG. Immunosensors for diagnostic applications. Parasitol. Res. 88(13 Suppl. 1), S4-S7 (2002).
49. Luppa PB, Sokoll LJ, Chan DW. Immunosensors -principles and applications to clinical chemistry. Clin. Chim. Acta. 314(1-2), 1-26 (2001).
50. Alvarez-Rueda N, Behar G, Ferre V et al. Generation of llama single-domain antibodies against methotrexate, a prototypical hapten. Mol. Immunol. 44(7), 1680-1690 (2007).
51. Yau KY, Groves MA, Li S et al. Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library. J. Immunol. Methods 281(1-2), 161-175 (2003).
52. Doyle PJ, Arbabi-Ghahroudi M, Gaudette N et al. Cloning, expression, and characterization of a single-domain antibody fragment with affinity for 15-acetyl-deoxynivalenol. Mol. Immunol. 45(14), 3703-3713 (2008).
53. Sonneson GJ, Horn JR. Hapten-induced dimerization of a single-domain VHH camelid antibody. Biochemistry 48(29), 6693-6695 (2009).
54. Choi JW, Oh BK, Kim YK, Min J. Nanotechnology in biodevices. J. Microbiol. Biotechnol. 17(1), 5-14 (2007).
55. Jain KK. Applications of nanobiotechnology in clinical diagnostics. Clin. Chem. 53(11), 2002-2009 (2007).
56. Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 16(2), 240-242 (2002).
57. Tanha J, Muruganandam A, Stanimirovic D. Phage display technology for identifying specific antigens on brain endothelial cells. Methods Mol. Med. 89, 435-449 (2003).